The ABPI is the body recognised by the Secretary of State for the purposes of negotiating a new voluntary scheme and being consulted on a statutory scheme, as set out in the National Health Service Act 2006.
The negotiations will begin in September and the ABPI has chosen a team which is representative of different sizes of companies as well as the different geographies.
The team representing the ABPI will be:
John Kearney, UK & Ireland General Manager of Amgen. He will serve as Chair of the team.
Pete Butterfield, Executive Director, Alliance.
Erik van Snippenberg, General Manager & Senior Vice-President UK, GSK
Jon Emms, Managing Director UK, Pfizer
Matthew Speers, Managing Director, British and Irish Isles, UCB.
They will be supported by an ABPI team led by Alison Clough, Commercial Director.
ABPI Press Office
Tel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7808 641810 or +44 (0) 7850 312064
Notes to editor
The voluntary scheme ( ie the PPRS) is the medicines pricing scheme which is negotiated between industry and Government.
The statutory scheme is the legislative scheme that controls medicines prices for those companies that choose not to participate in the voluntary scheme.
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by Government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.